REG - Inspiration Health - Results presentations for analysts and investors

Inspiration HealthcareAnnouncement

23/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250923:nRSW2860Aa&default-theme=true

RNS Number : 2860A  Inspiration Healthcare Group PLC  23 September 2025

 

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

 

Results presentations for analysts and investors

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology
company, announces it will host analyst and investor presentations on Tuesday,
7 October 2025, following the release of its interim results for the 6 months
ended 31 July 2025.

 

Analyst briefing

 

Raffi Stepanian CEO, and Alan Olby CFO, will host a briefing to equity
research analysts on Tuesday 7 October 2025 at 09.30am BST. To register and
for more details please contact Walbrook PR on
inspirationhealthcare@walbrookpr.com.

 

Investor presentation

 

Management will also provide a live presentation relating to the results via
the Investor Meet Company platform on Tuesday, 7 October 2025 at 11.00am BST.
 

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via the Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to
meet Inspiration Healthcare.

To register for the presentation, please do so here
(https://www.investormeetcompany.com/inspiration-healthcare-group-plc/register-investor)
.

 

Investors who already follow Inspiration Healthcare on the Investor Meet
Company platform will automatically be invited.

 

For further information, please contact:

 

 Inspiration Healthcare Group plc                                                          Tel: +44 (0)330
                                                           175 0000
 Raffi Stepanian, Chief Executive Officer

 Alan Olby, Chief Financial Officer

 Panmure Liberum (Nominated Adviser & Broker)                                                                                        Tel: +44 (0)20
                                                                                                     3100 2000
 Will Goode

 Emma Earl

 Mark Rogers

 Walbrook PR Ltd (Media & IR)      Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com
 Anna Dunphy                                               Mob: +44 (0) 7876 741 001
 Rachel Broad

 

About Inspiration Healthcare

 

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets
pioneering medical technology. Based in the UK, the Company specialises in
neonatal intensive care medical devices, which are addressing a critical need
to help to save the lives and improve the outcomes of patients, starting with
the very first breaths of life.

 

The Company has a broad portfolio of its own products and complementary
distributed products, for use in neonatal intensive care designed to support
even the most premature babies throughout their hospital stay. Its own branded
products range from highly sophisticated capital equipment such as ventilators
for life support through to single-use disposables.

 

The Company sells its products directly to hospitals and healthcare providers
in the UK and Ireland, where it also distributes a range of advanced medical
technologies for infusion therapy.  In the rest of the world the Company has
an established network of distribution partners around the world giving access
to more than 75 countries.

 

The Company operates in the UK from its world-class Manufacturing and
Technology Centre in Croydon, South London and in the USA from its facility in
Melbourne, Florida.

 

Further information on Inspiration Healthcare can be found
at www.inspirationhealthcaregroup.com
(http://www.inspirationhealthcaregroup.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBDGDCIDDDGUD